UPDATE | May 6, 2022

β-glucan as a Process-Related Impurity in Biopharmaceuticals

  • MAIL

WHITRPAPER

Global regulatory authorities and #CDMOs are taking steps to detect beta-glucans as well as understand their safety levels. When introduced into biopharma drug products via raw materials in the manufacturing process, beta-glucan impurities can lead to batch recalls and other quality issues. In this whitepaper, Soonbin Kwon, our Senior Scientist in MSAT, explores the source of the beta-glucan impurity, its influence on manufacturing and patient safety, and strategies to detect and control its amounts in the final drug product. 

WHITRPAPER

 

Global regulatory authorities and #CDMOs are taking steps to detect beta-glucans as well as understand their safety levels. When introduced into biopharma drug products via raw materials in the manufacturing process, beta-glucan impurities can lead to batch recalls and other quality issues. In this whitepaper, Soonbin Kwon, our Senior Scientist in MSAT, explores the source of the beta-glucan impurity, its influence on manufacturing and patient safety, and strategies to detect and control its amounts in the final drug product.
 

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required